Requiring coverage for certain pediatric autoimmune neuropsychiatric disorders in certain circumstances
Impact
If passed, SB297 would amend the West Virginia state code to include specific provisions for pediatric autoimmune neuropsychiatric disorders. It particularly focuses on enhancing coverage within the Public Employees Insurance Agency (PEIA) and Medicaid, extending vital health services to both state employees and Medicaid recipients. By mandating coverage for these treatments under certain conditions, the bill may lead to an increase in financial relief for families facing the costs of these therapies, thereby promoting better healthcare access for children in need of specialized care.
Summary
Senate Bill 297 is aimed at expanding insurance coverage for specific pediatric neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome. The bill proposes that health insurance plans must cover intravenous immunoglobulin therapy for these conditions, but only after obtaining prior authorization. This prior authorization requires physicians to demonstrate that all other treatment options have been exhausted before the coverage can be granted. The bill seeks to address gaps in coverage that have left certain treatment options inaccessible for affected children.
Sentiment
The sentiment surrounding SB297 is expected to be generally positive among families impacted by pediatric autoimmune neuropsychiatric disorders and healthcare advocates. Proponents argue that the bill is a necessary step towards recognizing and addressing significant health issues faced by pediatric populations. However, there may be polarized views regarding the prior authorization requirement, with some health professionals concerned that it may create additional barriers for families seeking timely treatment during critical periods.
Contention
While there is a broad acknowledgment of the importance of addressing pediatric neuropsychiatric disorders, notable points of contention may arise regarding the implementation of prior authorization protocols. Critics could argue that such requirements could hinder quick access to necessary treatments if not effectively managed. Additionally, the potential financial burden on insurance providers while trying to accommodate comprehensive coverage for these disorders may also be debated, raising broader questions about insurance regulations in the state.
Expiring funds to the unappropriated surplus balance in the State Fund, General Revenue, from the Department Revenue, State Budget Office, PEIA Rainy Day Fund
Insurance: insurers; coverage for certain pediatric autoimmune neuropsychiatric disorders; require. Amends 1956 PA 218 (MCL 500.100 - 500.8302) by adding sec. 3406pp.
Human services: medical services; coverage for the prophylaxis, diagnosis, and treatment of certain pediatric autoimmune neuropsychiatric disorders; require. Amends 1939 PA 280 (MCL 400.1 - 400.119b) by adding sec. 109v.
Removes the sunset provision of all statutory law requiring coverage for the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome.
Extends coverage for treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome by removing the sunset date of December 31, 2025, and mandating such coverage.